The typical new type 2 diabetes patient looks very different than in 2008

The kind of person who receives a new diagnosis of type 2 diabetes, and the way they are treated in the first weeks after, has been "fundamentally restructured" over roughly 15 years, according to a large records study from Israel [s1]. The paper, published in Diabetologia, compares two groups diagnosed in the same health system a decade and a half apart, and the contrast is sharp enough to complicate how the disease is pictured [s1].

The researchers used electronic health records from Clalit Health Services in northern Israel to compare adults with newly diagnosed type 2 diabetes in 2005-2008 (80,201 people) with those diagnosed in 2020-2023 (101,392 people) [s1]. Because both groups came from the same integrated system, the comparison holds the setting roughly constant while the years change [s1]. The bibliographic record for the study is dated 16 October 2026 [s2].

Older and sicker at diagnosis

People diagnosed in the recent period were older. Median age at diagnosis rose from 63.0 to 66.7 years, and the share aged 85 or older nearly doubled, from 3.5% to 6.6% [s1]. They also carried more other illness: the Charlson comorbidity index, a standard tally of coexisting conditions, rose from a score of 4 to 6 — a standardised mean difference of 0.48, which the authors treat as a meaningful shift rather than noise [s1].

One comorbidity jumped strikingly. Metabolic dysfunction-associated steatotic liver disease — MASLD, the fatty liver condition formerly called NAFLD — was recorded in 4.4% of the earlier group and 18.6% of the later one [s1]. The authors caution that most of this rise is "ascertainment-driven," meaning it largely reflects that the condition is now looked for and coded, not necessarily that four times as many patients truly have it [s1]. That caveat matters: a number that quadruples because of better detection tells a different story from one that quadruples because the disease is spreading.

But better controlled

Against the older, more complex picture, the recent patients arrived with their metabolic numbers in better shape. HbA1c at diagnosis — a measure of longer-term blood sugar — fell from 56 to 53 mmol/mol (7.3% to 7.0%) [s1]. LDL cholesterol before diagnosis dropped from 2.90 to 2.21 mmol/l, a standardised mean difference of 0.65, which the authors attribute largely to statin therapy already in place before the diabetes was identified [s1]. In other words, by the time diabetes is diagnosed today, many patients have already been pulled into cardiovascular prevention for other reasons.

A different first prescription

The treatment started in the first weeks changed most of all. Within 31 to 90 days of diagnosis, use of SGLT2 inhibitors rose from 0.07% to 15.0%, and GLP-1 receptor agonists — the class that includes drugs such as semaglutide and tirzepatide — from zero to 11.1% [s1]. Over the same span, sulfonylureas, an older and cheaper class, fell more than fourfold, from 20.8% to 4.5% [s1].

The authors read this as the "displacement of glucose-centric strategies by a cardiorenal- and weight-driven paradigm" [s1] — a shift from treating the blood-sugar number alone toward drugs chosen also for their effects on the heart, kidneys and weight. That tracks the last decade of trial evidence and guideline change, now visible in what patients are actually dispensed.

What it does and does not show

This is a retrospective cohort study, and its strengths and limits follow from that. Its strength is scale and consistency: two very large groups, from one system, compared with explicit statistical measures rather than eyeballed trends [s1]. Its limits are equally clear. It describes one integrated health system in one region of Israel, so the exact figures need not transfer elsewhere. It is descriptive, not causal — it shows that the picture changed, not why each piece changed. And part of the most dramatic finding, the rise in fatty liver disease, is flagged by the authors themselves as mostly an artefact of improved coding [s1].

The practical takeaway the authors draw is about who is now being diagnosed: older, frailer patients with more coexisting disease. They argue this points to a need for age-appropriate management and, pointedly, for trials that actually enrol the very elderly — the group increasingly showing up at diagnosis but routinely excluded from the studies that set treatment standards [s1]. For readers, the useful frame is that "newly diagnosed type 2 diabetes" is no longer the condition it was a generation ago, in who it strikes or how it is first treated.

This article is informational and does not constitute medical advice. Decisions about diabetes treatment belong with a patient and their clinician.